PURPOSE: Bortezomib, a proteasome inhibitor drug very effective against multiple myeloma, may induce the so-called bortezomib-induced peripheral neuropathy (BIPN), hardly manageable with common analgesic drugs. This study assessed the effectiveness of controlled-release (CR) oral oxycodone in controlling pain and its interference on daily functions of patients with hematologic malignancies affected by BIPN. METHODS: Forty-six patients (median age, 62 years) affected by myeloma and lymphoma, complaining of BIPN-related pain of moderate-to-severe intensity and unresponsive to previous analgesic treatments, were treated with CR oxycodone. The intensity of continuous and brief pain (BP) along with interference of pain with the common daily dimensions of feeling and function were evaluated by using an 11-point numerical rating scale (NRS); a global patient evaluation of efficacy was also performed. RESULTS: The daily average dose of CR oxycodone administered was 28.46 mg (range, 20-80 mg). The pain intensity decreased from a mean NRS value of 7.6 at baseline to 1.3 on day 14. The frequency of BP was reduced from 61 to 47% of patients and its intensity from 7.4 to 3.1 NRS score. A similar trend to decreasing values was observed for all the daily life functions. Slight- or mild-intensity side effects were observed in 23 patients (51%). At the end of the study, 75% of patients found the treatment effective or very effective. CONCLUSION: CR oxycodone for relief of BIPN-related pain was effective and well tolerated. The pain control significantly improved also the quality of the daily life functions, which are usually compromised in these suffering patients.
PURPOSE:Bortezomib, a proteasome inhibitor drug very effective against multiple myeloma, may induce the so-called bortezomib-induced peripheral neuropathy (BIPN), hardly manageable with common analgesic drugs. This study assessed the effectiveness of controlled-release (CR) oral oxycodone in controlling pain and its interference on daily functions of patients with hematologic malignancies affected by BIPN. METHODS: Forty-six patients (median age, 62 years) affected by myeloma and lymphoma, complaining of BIPN-related pain of moderate-to-severe intensity and unresponsive to previous analgesic treatments, were treated with CR oxycodone. The intensity of continuous and brief pain (BP) along with interference of pain with the common daily dimensions of feeling and function were evaluated by using an 11-point numerical rating scale (NRS); a global patient evaluation of efficacy was also performed. RESULTS: The daily average dose of CR oxycodone administered was 28.46 mg (range, 20-80 mg). The pain intensity decreased from a mean NRS value of 7.6 at baseline to 1.3 on day 14. The frequency of BP was reduced from 61 to 47% of patients and its intensity from 7.4 to 3.1 NRS score. A similar trend to decreasing values was observed for all the daily life functions. Slight- or mild-intensity side effects were observed in 23 patients (51%). At the end of the study, 75% of patients found the treatment effective or very effective. CONCLUSION:CR oxycodone for relief of BIPN-related pain was effective and well tolerated. The pain control significantly improved also the quality of the daily life functions, which are usually compromised in these suffering patients.
Authors: Pasquale Niscola; Claudio Romani; Claudio Cartoni; Luca Cupelli; Daniela Piccioni; Teresa Dentamaro; Andrea Tendas; Marco Giovannini; Laura Scaramucci; Barbara Tolu; Alessio Pio Perrotti; Paolo de Fabritiis Journal: Leuk Res Date: 2007-04-26 Impact factor: 3.156
Authors: Pasquale Niscola; Laura Scaramucci; Claudio Romani; Marco Giovannini; Luca Maurillo; Giovanni del Poeta; Claudio Cartoni; Edoardo Arcuri; Sergio Amadori; Paolo De Fabritiis Journal: Ann Hematol Date: 2006-03-30 Impact factor: 3.673
Authors: N Attal; G Cruccu; M Haanpää; P Hansson; T S Jensen; T Nurmikko; C Sampaio; S Sindrup; P Wiffen Journal: Eur J Neurol Date: 2006-11 Impact factor: 6.089
Authors: John Gerecitano; Carol Portlock; Craig Moskowitz; Paul Hamlin; David Straus; Andrew D Zelenetz; Zhigang Zhang; Otilia Dumitrescu; Debra Sarasohn; Dorothy Lin; Jennifer Pappanicholaou; Barbara M Cortelli; Ellen Neylon; Rachel Hamelers; John Wright; Owen A O'Connor Journal: Br J Haematol Date: 2009-07-16 Impact factor: 6.998
Authors: Pasquale Niscola; Claudio Cartoni; Claudio Romani; Gregorio Antonio Brunetti; Gianna Maria D'Elia; Luca Cupelli; Andrea Tendas; Paolo de Fabritiis; Franco Mandelli; Robin Foà Journal: Ann Hematol Date: 2007-04-21 Impact factor: 3.673
Authors: Pasquale Niscola; Alessio Pio Perrotti; Giovanni del Poeta; Claudio Romani; Massimiliano Palombi; Daniela Piccioni; Laura Scaramucci; Barbara Tolu; Andrea Tendas; Luca Cupelli; Elisabetta Abruzzese; Gianna Maria D'Elia; Gregorio Antonio Brunetti; Luca Maurillo; Marco Giovannini; Claudio Cartoni; Paolo de Fabritiis Journal: Herpes Date: 2007-09
Authors: Iwona Filipczak-Bryniarska; Roger M Krzyzewski; Jakub Kucharz; Anna Michalowska-Kaczmarczyk; Justyna Kleja; Jarosław Woron; Katarzyna Strzepek; Lucyna Kazior; Jerzy Wordliczek; Tomasz Grodzicki; Krzysztof Krzemieniecki Journal: Med Oncol Date: 2017-08-17 Impact factor: 3.064
Authors: Deirdre R Pachman; James C Watson; Maryam B Lustberg; Nina D Wagner-Johnston; Alexandre Chan; Larry Broadfield; Yin Ting Cheung; Christopher Steer; Dawn J Storey; Kavita D Chandwani; Judith Paice; Pascal Jean-Pierre; Jeong Oh; Jayesh Kamath; Marie Fallon; Herwig Strik; Susanne Koeppen; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-05-31 Impact factor: 3.359
Authors: Sarah Sloot; Jason Boland; John A Snowden; Yousef Ezaydi; Andrea Foster; Alison Gethin; Tracy Green; Louise Chopra; Stans Verhagen; Kris Vissers; Yvonne Engels; Sam H Ahmedzai Journal: Support Care Cancer Date: 2014-08-28 Impact factor: 3.603